drugset
drugset / Trial / NCT00899977

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977 ↗

Phase 1/2 Terminated 1 enrolled Targacept Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP \> 140 mmHg and a DBP \> 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.

Timeline

Start
2009-05
Primary completion
2009-08
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject dexmecamylamine Other / unclassified 1 mg Oral
Subject dexmecamylamine Other / unclassified 2 mg Oral
Subject dexmecamylamine Other / unclassified 4 mg Oral
Subject dexmecamylamine Other / unclassified 8 mg Oral

Indications

resistant hypertension